Şunu aradınız:: alloġeneiku (Maltaca - İngilizce)

hpct alloĠeneiku
allogeneic hpct

trapjant alloġeneiku tal-mudullun
bone marrow transplantation

għal mobilizzazzjoni tal-pbpcs f’donaturi normali qabel trapjant alloġeneiku tal-pbpc
for the mobilisation of pbpcs in normal donors prior to allogeneic pbpc transplantation

għall-mobilizzazzjoni tal-pbpc f’donaturi normali qabel trapjant alloġeneiku tal-pbpc
for the mobilisation of pbpcs in normal donors prior to allogeneic pbpc transplantation

għall-mobilizzazzjoni ta’ pbpcs f’donaturi normali qabel trapjant alloġeneiku tal-pbpc
for the mobilisation of pbpcs in normal donors prior to allogeneic pbpc transplantation

Ċ) il- kura jew prevenzjoni ta ’ infezzjonijiet wara trapjant tal- mudullun (trapjant alloġeneiku tal - mudullun).
c) treatment or prevention of infections after a bone marrow transplantation (allogeneic bone marrow transplantation).

fl-hpct alloġeneiku, il-kura ta’ kondizzjonament għandha tkun immunosoppressiva u majeloablattiva biżżejjed biex tegħleb ir-rifjut għat-trapjant.
in allogeneic hpct, the conditioning treatment must be sufficiently immunosuppressive and myeloablative to overcome host rejection of the graft.

studju retrospettiv ewropew li evalwa l-użu ta’ g-csf wara trapjant alloġeneiku tal-mudullun f’pazjenti b’lewkimji akuti, issuġġerixxa żieda fir-riskju ta’ gvhd, mortalità marbuta mal-kura (trm) u l-mortalità meta ngħata g-csf.
one retrospective european study evaluating the use of g-csf after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of gvhd, treatment related mortality (trm) and mortality when g-csf was administered.